


IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, Box 1450, Alexandria, VA 22313 on the date shown below:

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Patent Application  
Docket No. UF-368XC1  
Serial No. 10/809,631

September 24, 2004  
  
Margaret Efron, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Applicant(s) : Nathan Andrew Shapira, Toby Doris Goldsmith, Pierre Martin Blier  
Serial No. : 10/809,631  
Filed : March 24, 2004  
For : Methods for Treating Idiopathic Hyperhidrosis and Associated Conditions

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


Two of the cited references in the International Search Report are in a foreign language; however, to meet the duty of disclosure, the applicants have also included a copy of the International Search Report showing the relevancy of each of these cited references. The cited references in a

- 1) WO 03/011340 A1, February 13, 2003; and
- 2) NL 1014289, August 7, 2001.

Please note that WO 03/011340 reference has an English abstract.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



Margaret Efron  
Patent Attorney  
Registration No. 47,545  
Phone No.: 352-375-8100  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

MHE/la

Enclosure(s): Form PTO-1449;  
Copies of cited references; and  
Copy of International Search Report.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 1 of 2			<b>Complete if Known</b>	
			Application Number	10/809,631
			Filing Date	March 24, 2004
			First Named Inventor	Nathan Andrew Shapira
			Group Art Unit	1614
			Examiner Name	Unknown
			Attorney Docket Number	UF-368XC1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	U1	US 2002/103206	A1	Berendsen	08-01-2002	ALL
	U2					
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	F1		NL 1014289	C	Waldinger <i>et al.</i>	08-07-2001	ALL	
	F2		WO 03/011340	A1	Wohlrab Johannes	02-13-2003	ALL	
	F3		WO 99/52517	A2	Sigma Tau Ind. Farmaceuti.	10-21-1999	ALL	
	F4		WO 00/23057	A2	Janssen Pharmaceutica N.V.	04-27-2000	ALL	
	F5							
	F6							
	F7							

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please place a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/809,631		
		Filing Date	March 24, 2004		
		First Named Inventor	Nathan Andrew Shapira		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet		of		Attorney Docket Number	UF-368XC1

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	KRISTIANSEN, KURT <i>et al.</i> , "Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT receptor interactions," <i>European Journal of Pharmacology</i> (1996), 306:195-210.	
	R2	LE WITT, PETER, "Hyperhidrosis and hypothermia responsive to oxybutynin," <i>Neurology</i> (1988), 38:506-507.	
	R3	LI, JAMES P. <i>et al.</i> "Roles of 5-HT receptors in the release and action of secretion on pancreatic secretion in rats," <i>Am. J. Physiol.</i> (2001), 280:G595-G602.	
	R4	MARCY, R. <i>et al.</i> , "Anhidrotic Activity of Anti Cholinergics in Mice use of Different Routes of Administration," <i>Annales de Dermatologie et de Venereologie</i> (1977), 104:500-501.	
	R5	PASQUINI, M. <i>et al.</i> , "Mirtazapine for hyperhidrosis," <i>Psychosomatics</i> , United States (2003), 44(5):442-443.	
	R6	POMIER-LAYRARGUES, G. <i>et al.</i> , "Combined Treatment of Portal Hypertension with Ritanserin and Propranolol in Conscious and Unrestrained Cirrhotic Rats," <i>Hepatology</i> (1992), 15:878-882.	
	R7	SAADIA, DANIELA <i>et al.</i> , "Botulinum toxin type A in primary palmar hyperhidrosis: Randomized, single-blind, two-dose study," <i>Neurology</i> (2001), 57:2095-2099.	
	R8	SCHMIDT, ANNE W. <i>et al.</i> , "Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile," <i>European Journal of Pharmacology</i> (2001), 425:197-201.	
	R9	SEVILLE, R. H. <i>et al.</i> , "Treatment of Hyperhidrosis with Topical Propantheline -- a New Technique," <i>British Journal of Dermatology</i> (1972), 86:441.	
	R10	WILLIAMS, F. M. <i>et al.</i> , "Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers," <i>British Journal of Clinical Pharmacology</i> (1986), 22:301-308.	
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.